首页> 外国专利> HCV Envelope Proteins glycated in the central structure, a method for producing the Envelope Protein of HCV isolated, a composition that includes a method to detect the presence of Anti HCV Antibodies in a Sample, a Diagnostic KIT to detect the presence of ant

HCV Envelope Proteins glycated in the central structure, a method for producing the Envelope Protein of HCV isolated, a composition that includes a method to detect the presence of Anti HCV Antibodies in a Sample, a Diagnostic KIT to detect the presence of ant

机译：在中心结构中糖化的HCV信封蛋白，分离的HCV信封蛋白的生产方法，包括检测样品中抗HCV抗体存在的方法，诊断试剂盒以检测蚂蚁的存在的组合物

页面导航

摘要
著录项
相似文献

摘要

A protein of the envelope of HCV isolated or its fragment comprising at least one n-linked glycosylation site, The Protein or its fragment is the product of expression of a eukaryotic cell and is on average up to 80% of the n-linked glycosylation sites are glycosylated in the Central structure.These N - glycosylated sites, more than 70% are glycosylated with a oligomanosa possesses a structure defined by Man (8 to 10) - GlcNAc (2). In addition, the relationship of the oligomanosa with Structure Man GlcNAc - (7) (2) on the oligomanosa with Structure Man GlcNAc - (8) (2) is less than or equal to 0.45. Less than 10% of the oligomanosas end with a link alfa1,3 Mannose.The envelope Proteins of HCV are suitable in particular for Diagnostic, prophylactic and therapeutic.A eukaryotic Cell suitable for the production of the HCV Envelope Proteins is a Hansenula Cell; a method for producing the Envelope Protein of HCV isolated, a composition that includes a method to detect the presence of Anti HCV Antibodies in a Sample Tra, a Diagnostic KIT to detect the presence of Anti HCV Antibodies, a drugPharmaceutical composition, a Diagnostic KIT and Vaccine.8: the claim of the Envelope Protein of HCV isolated or its fragment according to claim 7 derived from a Protein characterized by Structure: CL - [(A1) - (PS1) B - (A2) hcvenv [c] - (A3) - D - e - (A4 (PS2) (f)] where: CL is a Leader of Avian Lysozyme Peptide or its equivalent F Uncional; A1, A2.A3 and A4 are Adaptors that peptides may be different or the same, PS1 and PS2 are Processing sites that may be different or the same; hcvenv is a Protein of the HCV Envelope or a part thereof; a, B, C, D, e and F are 0 OR 1; and in the Optionally, A1, A2 and / or os Part of PS1 and / or the A3 and A4 / or are part of PS2.

机译：分离的HCV包膜蛋白或其片段包含至少一个n-连接的糖基化位点，该蛋白或其片段是真核细胞表达的产物，平均最多占n-连接的糖基化位点的80％这些N-糖基化位点中，超过70％被寡糖寡糖糖基化，其结构由Man（8至10）-GlcNAc（2）定义。另外，具有结构Man GlcNAc-（7）（2）的寡聚体与具有结构Man GlcNAc-（8）（2）的寡聚体的关系小于或等于0.45。少于10％的寡核苷酸末端带有连接alfa1,3甘露糖。HCV的包膜蛋白特别适用于诊断，预防和治疗。适于生产HCV包膜蛋白的真核细胞是汉逊酵母细胞。一种分离的HCV包膜蛋白的生产方法，一种组合物，其包括检测样品Tra中抗HCV抗体的存在的方法，检测抗HCV抗体的存在的诊断KIT，药物药物组合物，诊断KIT和疫苗8：权利要求7的分离的HCV包膜蛋白或其片段的权利要求，其衍生自以下蛋白质，其特征在于结构：CL-[（A1）-（PS1）B-（A2）hcvenv [c]-（A3 ）-D-e-（A4（PS2）（f）]其中：CL是禽溶菌酶肽的前导子或等同的F Uncional; A1，A2.A3和A4是肽可能不同或相同的衔接子，PS1 PS2和PS2是可能不同或相同的加工位点; hcvenv是HCV信封的蛋白质或其部分; a，B，C，D，e和F为0或1;在可选情况下，A1，A2和 /或PS1的一部分和 /或A3和A4 /或PS2的一部分。

著录项

公开/公告号AR035869A1

专利类型
公开/公告日2004-07-21

原文格式PDF
申请/专利权人 INNOGENETICS N.V.;
展开▼

申请/专利号AR2002P101495
发明设计人
展开▼

申请日2002-04-24
分类号C07K14/18;C07K1/14;C07K1/107;C07K1/113;C12N7/00;C12N1/19;C12N15/81;C12N15/62;A61K39/29;A61K35/76;G01N33/53;G01N33/543;
国家 AR
入库时间 2022-08-21 23:12:23

相似文献

专利
外文文献
中文文献